1.Prognostic and Therapeutic Significance of Molecular Subtyping on Aged Patient with Advanced Diffuse Large B Cell Lymphoma---A Case Report.
Li-Jun XIN ; Bo YANG ; Xue-Chun LU ; Peng YIN ; Ye TIAN ; Hong-Li ZHU
Journal of Experimental Hematology 2016;24(2):457-462
OBJECTIVETo analyze the clinical course of a very elderly patient with advanced diffuse large B cell lymphoma (DLBCL), so as to explore the incidence, prognosis and treatment of DLBCL and to analyse the prognostic and therapeutic significance of molecular subtype.
METHODSThe clinical history, auxiliary examinations, clinical diagnostic standards, therapeutic methods, biopsy and autopsy of this patient were retrospectively analyzed; the incidence, current treatment status, molecular biological features, and prognostic and therapeutic significance of molecular subtype were studied.
RESULTSAfter admission, this patient was diagnosed as non-GCB DLBCL, NOS, stage IV B and in the high risk group (IPI = 5, ECOG = 2). She achieved a decent partial response after many times of imunochemotherapy, but his disease status soon progressed. The liver occupying biopsy revealed non-GCB, while the spleen tumor pathology revealed GCB; pathological typing of these two methods was completely opposite. Autopsy pathological diagnosis showed that the death causes included extensive tumor metastasis, dyscrasia and respiratory circle failure.
CONCLUSIONIncidence of aged patients with DLBCL is high, and the disease is aggressive; the treatment is low responsive and difficult, and new therapeutic methods are needed. Gene expression profile (GEP) can provide molecular subtype and potential pathogenic mechanism, which can promote the development of new targeted therapy and individualized treatment.
Aged ; Female ; Humans ; Lymphoma, Large B-Cell, Diffuse ; diagnosis ; pathology ; therapy ; Neoplasm Staging ; Prognosis
2.Three Cases of Diffuse Large B-Cell Lymphoma Presenting as Primary Splenic Lymphoma.
Ja Kyung KIM ; Jee Sook HAHN ; Gwi Eon KIM ; Woo Ick YANG
Yonsei Medical Journal 2005;46(5):703-709
Primary splenic lymphoma (PSL) is often defined as generalized lymphoma with splenic involvement as the dominant feature. It is a rare disease that comprises approximately 1% of all malignant lymphomas. We investigated three cases of non-Hodgkin's splenic lymphoma that had different clinical features on presentation. The patients' survival times from diagnosis ranged from 59 to 143 months, without evidence of relapse after splenectomy and chemotherapy, with or without radiotherapy. This data suggest that PSL is potentially curable. Further studies are needed to evaluate the impact that different treatment modalities without splenectomy have on patient survival.
Splenic Neoplasms/*diagnosis/pathology/therapy
;
Splenectomy
;
Middle Aged
;
Male
;
Lymphoma, Large-Cell, Diffuse/*diagnosis/pathology/therapy
;
Lymphoma, B-Cell/*diagnosis/pathology/therapy
;
Humans
;
Female
3.A Case of Primary Pancreatic Non-Hodgkin's Lymphoma.
Myung Kwon LEE ; Seong Woo JEON ; Young Doo LEE ; Hyang Eun SEO ; Chang Min CHO ; Sang Gul KIM ; Young Kook YOON
The Korean Journal of Internal Medicine 2006;21(2):123-126
Primary pancreatic lymphoma is rare, comprising 0.2~4.9% of all pancreatic malignancies and less than 1% of cases of non-Hodgkin's lymphoma. Many patients are diagnosed with lymphoma after radical resection. We report a rare presentation of diffuse large B cell lymphoma, appearing as a primary tumor of the pancreas. A 61-year old female was admitted to the hospital with the complaint of right upper abdominal pain. Computed tomography of the abdomen showed a well defined mass located at the head of the pancreas. A frozen section of pancreas, during laparotomy, revealed lymphoma. The patient received 6 cycles of chemotherapy and is currently in complete remission. This case underscores the importance of differentiating primary lymphoma from the more common adenocarcinoma of the pancreas as treatment and prognosis differ significantly. Primary pancreatic lymphoma should be considered in the differential diagnosis of pancreatic tumors and an attempt to obtain a tissue diagnosis is always necessary before proceeding to radical surgery, especially on young patients.
Pancreatic Neoplasms/diagnosis/pathology/*therapy
;
Middle Aged
;
Lymphoma, Large-Cell, Diffuse/diagnosis/pathology/*therapy
;
Lymphoma, B-Cell/diagnosis/pathology/*therapy
;
Humans
;
Female
4.Analysis of Clinicopathological Characteristics and Prognosis of 112 Patients with Primary Waldeyer's Ring Lymphoma.
Da-Lin GAO ; Qian-Qian FU ; Tian-Tian ZHANG ; Shao-Ling LI ; Yi PAN ; Qiong-Li ZHAI
Journal of Experimental Hematology 2015;23(5):1301-1308
OBJECTIVETo investigate the clinical and pathological characteristics of patients with primary Waldeyer's ring lymphomas (PWRL), and to analyze its therapeutic efficacy and prognostic factors.
METHODSA total of 112 patients with PWRL confirmed by pathological and immunohistochemical methods between January 2009 and January 2014 were studied. Clinical data were collected and analyzed retrospectively.
RESULTSPWRL accounted for 3.9% of lymphoma over the same period. Median age of patients with PWRL was 51.5 years old. The affected areas were tonsil, nasopharynx, tongue base and oropharynx, which accounted for 63.4% (71/112), 22.3% (25/112), 5.3% (6/112) and 4.5% (5/112) respectively. The most common pathological types of these four areas were diffused large B-cell lymphoma (DLBCL) and extranodal NK/T cell lymphoma (NKTCL) which accounted for 58% and 15.2%. The overall response rate (CR/CRu = 51.4%; PR = 30.8%) in all patients was 82.2%, the estimated 5-year overall survival (OS) rate were 71.6%. The 5-year OS rate were 94.7% in the group used Rituximab. Meanwhile, chemotherapy combined with radiotherapy could improve the outcome of T-cell PWRL patients and the 5-year OS rate were 88.9%. Age, disease stages, pathological types, IPI scores, LDH level, β2-MG level and the efficacy of initial therapy were prognostic factors with statistical significance. Cox multivariate analysis showed that age of more than 60 years, LDH level, pathological types and the efficacy of the initial therapy were independently associated with OS.
CONCLUSIONPWRL has a relatively good prognosis. The pathological types affect the prognosis directly and guide treatment. Combined modality therapy should be chosen for patients with PWRL. Patients with T-cell PWRL should accept chemotherapy combined with radiotherapy, while rituximab may be better for B-cell PWRL. The efficacy of initial therapy is crucial for the outcome of patients. Age and LDH level are also important prognostic factors.
Combined Modality Therapy ; Humans ; Lymphoma, Extranodal NK-T-Cell ; diagnosis ; pathology ; Lymphoma, Large B-Cell, Diffuse ; diagnosis ; pathology ; Middle Aged ; Multivariate Analysis ; Prognosis ; Retrospective Studies ; Rituximab ; Survival Rate
5.Primary Breast Diffuse Large B Cell Lymphoma: Summarization of 12 Cases.
Ying HUANG ; Li WANG ; Lei FAN ; Tian TIAN ; Xiao-Yan QU ; Ji XU ; Run ZHANG ; Wei XU ; Jian-Yong LI
Journal of Experimental Hematology 2016;24(2):452-456
OBJECTIVETo investigate the clinicopathological manifestation, immunophenotypic features and prognostic factors of patients with primary breast DLBCL (PB-DLBCL).
METHODSTwelve cases of PB-DLBCL, diagnosed according to the 2008 World Health Organization classification of tumors of hematopoietic and lymphoid tissues, were retrospectively studied.
RESULTSMost patients were admitted to hospital because of painless unilateral breast mass. Out of 12 cases, 5 were in Ann Arbor stage I (41.7%), 7 case were in stage II (58.3%). Most (89.9%) were assigned to non-GCB subtypes, 11.1% were classified as GCB subtype. The patients who recepted treatment were sensitive to chemotherapy and they were all alive following 12 to 92 months.
CONCLUSIONPrimary breast DLBCL is extremely rare without specific clinical features. They all respond well to chemotherapy and show good prognosis.
Breast Neoplasms ; diagnosis ; pathology ; therapy ; Humans ; Lymphoma, Large B-Cell, Diffuse ; diagnosis ; pathology ; therapy ; Neoplasm Staging ; Prognosis ; Retrospective Studies ; Survival Rate
6.Clinical features of 50 cases of primary gastric lymphoma.
Jin HUANG ; Meizuo ZHONG ; Youhong TANG ; Jianhong LU ; Xiaoling LI ; Guiyuan LI
Journal of Central South University(Medical Sciences) 2012;37(10):997-1002
OBJECTIVE:
To analyze the clinical characteristics of primary gastric lymphoma (PGL) and to improve its diagnosis and treatment.
METHODS:
The clinical manifestations, diagnosis, treatments and history of 50 PGL patients, who were hospitalized from September 2005 to September 2009, were reviewed and analyzed.
RESULTS:
The main manifestation of PGL was epigastric pain with infrequent systemic symptoms, such as stomach ache, abdominal discomfort, vomit, black stool, loss of appetite, fever, feeble, and skinny. Pathological examination indicated that only 1 patient had T cell lymphoma while the rest 49 had B cell lymphoma. Fourteen had mucosa-associated lymphoid tissue lymphoma (MALT), 35 had diffuse large B cell lymphoma (DLBCL), and 2 had both DLBCL and MALT (DLBCML). All the 50 patients received chemotherapy, and 12 underwent surgical treatment besides chemotherapy. Fourteen out of the 49 patients with B cell lymphoma received rituximab together with chemotherapy, and 35 received chemotherapy alone. The 2-year survival rate in the patients receiving rituximab together with chemotherapy was higher than that in the patients receiving chemotherapy alone (85.7% vs 77.1%, P< 0.05). The 2-year survival rate in patients of clinical stage I-II was higher than that in patients of clinical stage III-IV (90.9% vs 71.4%, P< 0.05).
CONCLUSION
The main clinical manifestation of PGL patients is non-specific gastrointestinal symptoms, among which abdominal pain is most common. The clinical examination mainly relies on pathological examinations, and the most common pathological type of primary gastric lymphoma is DLBCL. The main treatment is chemotherapy, and the prognosis is related to the clinical stage and the use of rituximab. After the treatment, the 2-year survival rate in the 50 patients reaches 80.0%.
Antibodies, Monoclonal, Murine-Derived
;
therapeutic use
;
Humans
;
Lymphoma, B-Cell, Marginal Zone
;
Lymphoma, Large B-Cell, Diffuse
;
Lymphoma, Non-Hodgkin
;
diagnosis
;
drug therapy
;
pathology
;
Prognosis
;
Retrospective Studies
;
Rituximab
;
Stomach Neoplasms
;
diagnosis
;
drug therapy
;
pathology
;
Survival Rate
7.The clinical characteristics and prognostic analysis of 147 cases of diffuse large B-cell lymphoma.
Qian ZHAO ; Wei-jun FU ; Chun-yang ZHANG ; Juan DU ; Hao XI ; Jian HOU
Chinese Journal of Hematology 2013;34(9):737-740
OBJECTIVETo investigate the relationship between the clinical features, pathogenesis, immunophenotype, different classification models and prognosis in Chinese patients with diffuse large B-cell lymphoma (DLBCL).
METHODSA total of 147 patients with DLBCL who were treated with CHOP-like or R-CHOP were subjected to analysis. Standard two-step Envision method of immunohistochemical staining was used to assess the expression of CD10, Bcl-6, MUM1, FOXP1, GCET1, CD5, Bcl-2, Ki-67, then according to Hans algorithm, Choi algorithm and Molecular markers, we compared the differences of their prognoses.
RESULTS(1) Kaplan-Meier univariate analysis of the clinical data of 147 DLBCL patients found that the 3-year overall survival (OS) rates were better in early stage (P=0.032), low IPI score (P=0.001), less than one extranodal involvement (P=0.014), and complete remission (P<0.01). The prognoses had no significant difference in terms of gender, age, LDH, B symptoms and treatment options (P value> 0.05). (2 )For Hans model, GCB group had 42 cases, the ABC group 85 cases; GCB were 47 cases, ABC 80 cases (according to Choi model). Choi model suggested GCB subtype showed much better prognosis than ABC subtype (P=0.047), while Hans model shed no statistically significant difference (P=0.285). (3) Ki-67 of 75% was found to significantly discriminate patients with good or bad prognosis. In R-CHOP group at the same time, low Ki-67 (P=0.017) and CD5-negative groups (P=0.012) were better. Cox proportional hazards regression model showed that IPI score (P=0.002) and Ki-67 (P=0.019) were independent adverse prognostic factors.
CONCLUSIONThe Ann Arbor stage, IPI score, extranodal involvement status and Ki-67 were significantly associated with prognosis .Compared to Hans algorithm, Choi had an advantage to predict the different prognosis between subtypes, and ABC group had poor outcome. Finally, both Ki-67 and IPI score were independent adverse prognostic factors.
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Immunophenotyping ; Lymphoma, Large B-Cell, Diffuse ; diagnosis ; pathology ; therapy ; Male ; Middle Aged ; Prognosis ; Young Adult
8.Primary cutaneous diffuse large B-cell lymphoma, leg type: report of a case.
Xiao-yu LU ; Chen LU ; Yu-lei YIN ; Bo YU
Chinese Journal of Pathology 2010;39(6):416-417
Antigens, CD20
;
metabolism
;
Antineoplastic Combined Chemotherapy Protocols
;
therapeutic use
;
Diagnosis, Differential
;
Humans
;
Leg
;
Lymphoma, Follicular
;
metabolism
;
pathology
;
Lymphoma, Large B-Cell, Diffuse
;
drug therapy
;
metabolism
;
pathology
;
Male
;
Middle Aged
;
Neoplasm Recurrence, Local
;
Skin Neoplasms
;
drug therapy
;
metabolism
;
pathology
9.CD56-positive diffuse large B-cell lymphoma: report of a case.
Bo CHEN ; Wen-yong SUN ; Juan LUO ; Gu ZHANG
Chinese Journal of Pathology 2010;39(5):343-344
Adult
;
CD56 Antigen
;
metabolism
;
Combined Modality Therapy
;
Diagnosis, Differential
;
Humans
;
Lymphoma, Extranodal NK-T-Cell
;
metabolism
;
pathology
;
Lymphoma, Large B-Cell, Diffuse
;
metabolism
;
pathology
;
therapy
;
Lymphoma, Large-Cell, Anaplastic
;
metabolism
;
pathology
;
Male
;
Neprilysin
;
metabolism
;
Proto-Oncogene Proteins c-bcl-6
;
metabolism
10.Primary breast diffuse large B-cell lymphoma-report of 21 cases from China with literatures review.
Xing SUN ; Bin XU ; Yufu LI ; Jianwei DU ; Lihua DONG ; Xue GAO ; Gangping LI ; Xudong WEI ; Yongping SONG
Chinese Journal of Hematology 2015;36(10):853-857
OBJECTIVETo evaluateclinical features, treatment and outcomes of patients diagnosed with primary breast diffuse large B-cell lymphoma(DLBCL).
METHODSClinical data were analyzed for all patients diagnosed with primary breast DLBCL(n=21). Kaplan-Meier method was used to estimate 5- year overall survival(OS)rate, and the difference was compared by Log- rank test.
RESULTSThe 21 cases of patients with primary breast DLBCL were all female with median age at diagnosis as 48 years (range 21-64 years). 13 patients had International Prognostic Index(IPI)of 0, 6 IPI 1, and 2 IPI 2. The 5- year OS rates of CHOP/R- CHOP and R±DICE after R±EPOCH groups were 40.0% and 72.2% , respectively(P=0.035). The central nervous system relapse rate of CHOP/R-CHOP and R±DICE after R± EPOCH groups were 16.7% and 6.7%(P=0.500), respectively. The 5- year OS rates of patients with primary breast DLBCL staging Ⅱ E-Ⅲ E and Ⅰ E were 21.4% and 83.3% , respectively(P=0.025).
CONCLUSIONPrimary breast DLBCL was rare. The patients of primary breast DLBCL with chemotherapy regimen of R±DICE after R±EPOCH might have a better prognosis and lower relapse rate of central nervous system; the primary breast DLBCL patients staging ⅡE-ⅢE might have a poor prognosis.
Antibodies, Monoclonal, Murine-Derived ; Antineoplastic Combined Chemotherapy Protocols ; Breast Neoplasms ; diagnosis ; drug therapy ; pathology ; China ; Cisplatin ; Cyclophosphamide ; Dexamethasone ; Doxorubicin ; Etoposide ; Female ; Humans ; Ifosfamide ; Lymphoma, Large B-Cell, Diffuse ; diagnosis ; drug therapy ; pathology ; Neoplasm Recurrence, Local ; Prednisone ; Prognosis ; Retrospective Studies ; Vincristine